Tag: Biologics

Domestic manufacturers have petitioned for tax reliefs—such as income‑tax exemptions on new molecular entities—to incentivize high‑risk R&D

This acquisition positions Zydus at the forefront of the fast-growing global biologics CDMO market, establishing a robust presence in the world’s leading biotech innovation hub

The Cover Story analyses the potential impact of significant uncertainty due to the proposed reciprocal tariffs with insights from Vishal Dhikale, Associate Vice President, Avalon Consulting. Read interview of Puneeth Kumar KT, Business Director for Planetary Health Biosolutions, Novonesis South Asia and Expert Insights by Mahesh Ramanujam, President & CEO, Global Network for Zero; and Dr Vidhi Bhanushali, CEO and Co-founder, scanO.

Raichur site is the group’s largest API facility and part of a wider network of seven sites

The Cover Story analyzes the blockbuster opportunity for India's biopharma industry. Read interviews of Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited; Sachin Joshi, MD & Founder, PharmNXT Biotech; Mandeep Singh Kumar, MD and Vice President, Medtronic India; and Harshvardhan Bhagchandka, President, IPL Biologicals

Through a series of collaborative and acquisition deals, company aims to develop a unique delivery model tailored for its customers

The next-generation continuous manufacturing platform aims to reduce production costs by 50%, enhancing productivity for commercial biologics

Approval from equity shareholders and secured creditors marks a major milestone in the creation of OneSource

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan

Revolutionary HILOPRO® technology to enhance subcutaneous delivery of high-concentration biologics, boosting OneSource’s scientific services